Rapid antifungal treatment improves survival rates for patients with Candida septic shock
A study involving Manitoba researchers found that the time taken to start appropriate antifungal therapy is the most significant factor for survival in Candida septic shock. Patients treated within two hours of persistent hypotension had an 86% survival rate, with outcomes worsening by 5% for every hour of delay thereafter.
For patients with suspected Candida septic shock, prioritizing the rapid administration of appropriate antifungal therapy within the first two hours of hypotension is critical.
Ask about this brief
Answers are written by AI from this brief and can be wrong. Check the original source before you act.
2 free questions a day without an account. Members ask as often as they like, free.
Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.
Read the original
Official source: Rapid antifungal treatment improves survival rates for patients with Candida septic shock (opens in a new tab) — Manitoba health research (PubMed)
